Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies

  • Beck A
  • Debaene F
  • Diemer H
 et al. 
  • 75


    Mendeley users who have this article in their library.
  • 46


    Citations of this article.


The approval process for antibody biosimilars relies primarily on comprehensive analytical data to establish comparability and high similarity with the originator. Mass spectrometry (MS) in combination with liquid chromatography (LC) and electrophoretic methods are the corner stone for comparability and biosimilarity evaluation. In this special feature we report head-to-head comparison of trastuzumab and cetuximab with corresponding biosimilar and biobetter candidates based on cutting-edge mass spectrometry techniques such as native MS and ion-mobility MS at different levels (top, middle and bottom). In addition, we discuss the advantages and the limitations of sample preparation and enzymatic digestion, middle-up and -down strategies and the use of hydrogen/deuterium exchange followed by MS (HDX-MS). Last but not least, emerging separation methods combined to MS such as capillary zone electrophoresis-tandem MS (CESI-MS/MS), electron transfer dissociation (ETD), top down-sequencing (TDS) and high-resolution MS (HR-MS) that complete the panel of state-of-the-art MS-based options for comparability and biosimilarity evaluation are presented.

Author-supplied keywords

  • antibody
  • biobetter
  • biosimilar
  • cetuximab
  • critical quality attribute
  • glycosylation
  • mass spectrometry
  • trastuzumab

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Alain Beck

  • Fran??ois Debaene

  • H??l??ne Diemer

  • Elsa Wagner-Rousset

  • Olivier Colas

  • Alain Van Dorsselaer

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free